Cytogem Injection 1 gm/26.3 ml contains Gemcitabine, a powerful chemotherapeutic agent widely used for the treatment of various solid tumors. Gemcitabine is classified as an antimetabolite, a type of drug that interferes with DNA synthesis, effectively inhibiting the growth and proliferation of rapidly dividing cancer cells.

Cytogem is formulated for intravenous administration and is intended for use in hospitals or oncology centers under strict medical supervision. This high-dose formulation is suitable for patients requiring larger doses as part of standard chemotherapy regimens or combination therapies. It provides precise dosing, flexibility, and ease of administration while maintaining stability and efficacy.

Gemcitabine is commonly used to treat cancers such as pancreatic cancer, non-small cell lung cancer (NSCLC), breast cancer, ovarian cancer, and other solid tumors. It can be administered alone or in combination with other chemotherapeutic agents to enhance therapeutic outcomes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Mechanism of Action

Gemcitabine is a nucleoside analog, structurally similar to deoxycytidine. After entering cancer cells, it is converted into its active triphosphate form, which incorporates into the DNA during replication. This incorporation leads to premature termination of DNA synthesis, preventing cancer cell proliferation.

Additionally, Gemcitabine inhibits ribonucleotide reductase, an enzyme critical for the production of deoxyribonucleotides required for DNA synthesis. This dual action disrupts DNA replication and promotes apoptosis (programmed cell death) in rapidly dividing cells.

Because healthy cells generally divide more slowly than cancer cells, Gemcitabine selectively targets tumor tissue while minimizing toxicity to normal tissues.

Indications

Cytogem Injection 1 gm/26.3 ml is indicated for the treatment of:

• Pancreatic cancer (locally advanced or metastatic)

• Non-small cell lung cancer (NSCLC)

• Breast cancer

• Ovarian cancer

• Combination therapy for other solid tumors requiring enhanced antitumor activity

It is particularly effective in cancers with high mitotic activity and is frequently incorporated into standard oncology treatment protocols.

Dosage and Administration

The dosage of Cytogem Injection 1 gm/26.3 ml depends on the patient’s body surface area (BSA), type of cancer, and whether it is used as monotherapy or in combination with other drugs. It is administered intravenously over a set period, often on a weekly schedule for multiple cycles, with rest periods in between to allow recovery of normal cells.

Patients must be closely monitored for blood counts, liver and kidney function, and overall tolerance to therapy. Dosage adjustments may be required in cases of organ impairment, severe side effects, or hematological toxicity.

Precautions and Warnings

• Administer only under medical supervision in a clinical setting.

• Patients with liver or kidney impairment, infections, or low blood counts require special monitoring.

• Gemcitabine may cause fetal harm; pregnancy should be avoided during treatment.

• Immunosuppressed patients are at higher risk of infections; infection prevention is essential.

• Healthcare providers should handle the drug with care, as it is cytotoxic.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects include:

• Nausea and vomiting

• Fatigue and weakness

• Low blood counts (anemia, neutropenia, thrombocytopenia)

• Fever or increased risk of infections

• Rash or flu-like symptoms

• Rare cases of liver or kidney dysfunction

Supportive therapies, hydration, and monitoring are critical to managing side effects effectively.

Storage Instructions

Store Cytogem Injection 1 gm/26.3 ml in a cool, dry place, protected from light. Keep out of reach of children. Reconstituted or diluted solutions should be prepared and administered immediately following hospital protocols.

Cytogem Injection 1 gm/26.3 ml is an essential chemotherapy agent, offering potent antitumor activity for a variety of solid cancers while allowing flexible dosing for individualized treatment plans.